Document:

Blueprint

  Exhibit 4.1

 

PROMISSORY NOTE

 

	

$20,000.00

	

September
10, 2018

 

FOR
VALUE RECEIVED, Sunshine Biopharma, Inc, a Colorado Corporation
with an address at 6500 Trans-Canada Highway, 4th Floor,
Pointe-Claire, Quebec, Canada H9R 0A5 (referred to herein as
“Debtor”), hereby
irrevocably promises and agrees to pay to the order of GHS
Investments, LLC a Nevada Limited Liability Company with an address
at 420 Jericho Turnpike, Suite 207, Jericho, NY 11753
(“Creditor”), or at such
other place as set forth herein or as designated in writing by the
Holder (as defined below) hereof, in lawful money of the United
States of America, the principal sum of Twenty Thousand Dollars
($20,000), together with interest thereon (if any) and other fees
in connection therewith, all in accordance with the terms and
conditions set forth below.

 

1. Interest on
the unpaid principal balance hereof will accrue from the date
hereof at the rate of eight percent (8%) per annum, calculated on
the basis of a 365-day year and actual days elapsed until the
entire outstanding balance and all interest accrued thereon has
been repaid in full.

 

2. Creditor
may sell, assign, transfer, pledge or hypothecate this Note and any
or all of its rights and remedies hereunder at any time, with or
without notice to Debtor, to any person or entity. Creditor and its
successors and assigns under this Note are sometimes referred to
herein as the “Holder.”

 

3. Full
Payment on this Note will be due and payable on or before June 30,
2019. Payment shall be delivered to Creditor’s address, or to
such other address as directed in writing by the Holder hereof, and
shall be made in U.S. Dollars in immediately available
funds.

 

4. Debtor may
prepay any amount due hereunder, in whole or in part, at any time
without penalty or premium for such early payment. Debtor shall
also be entitled to offset against this Note any amount owed by
Creditor to Debtor, including without limitation any losses or
expenses actually incurred by Debtor as a result of a breach by
Creditor of any of its obligations between Debtor and
Creditor.

 

5. If after a
ten day (10) cure period, (a) any payment or delivery required by
this Note is not made when due hereunder, or any obligation or
covenant undertaken by Debtor hereunder is not performed or
observed as and when required hereby, (b) Debtor defaults in the
performance of any obligation evidenced by this Note, (c) any
representation or warranty made by Debtor in this Note or any other
instrument, agreement or document delivered by Debtor or any other
party for Debtor’s benefit in connection herewith proves to
have been materially false or inaccurate when made, (d) any event
of default occurs under any instrument securing the obligations
evidenced by this Note, or (e) Debtor files an assignment for the
benefit of creditors or for relief under any provisions of the
Bankruptcy Code, or suffers an involuntary petition in bankruptcy
or receivership to be filed and not vacated within 30 days, then
the Holder may at its sole option consider the entire unpaid
principal balance and accrued but unpaid interest hereunder at once
become due and payable without notice (time being the essence
hereof). The exercise or failure to exercise such remedy shall not
constitute a waiver of the right to exercise such remedy or
preclude the exercise of any other remedy in the event of any
subsequent default, event or circumstance that gives rise to such
right of acceleration.

 

6. In the
event Debtor fails to make a payment under this Note on the due
date therefore or otherwise defaults in any obligation under this
Note, all amounts owing and past due hereunder, including without
limitation principal (whether by acceleration or in due course),
interest, late fees and other charges, shall become immediately due
bear interest at the rate of eighteen percent (18%) per annum or
the maximum rate allowed by law, both before and after
judgment.

 

 

 

 

7. In the
event that any payment under this Note is not made at the time and
in the manner required (whether before or after maturity), Debtor
agrees to pay any and all reasonable costs and expenses which may
be incurred by Holder in connection with the enforcement of any of
its rights under this Note, including, but not limited to,
reasonable attorneys’ fees and all costs and expenses of
collection.

 

8. All amounts
paid by Debtor in respect of amounts due hereunder shall be applied
by Holder in the following order of priority:(a) amounts due and
payable, if any, pursuant to Paragraph 8 above, (b) interest due
and payable hereunder, and (c) the outstanding principal balance
hereof.

 

9. Debtor, on
behalf of itself and all sureties, guarantors, and endorsers
hereof, if any, hereby waives presentment for payment, demand, and
notice of dishonor and nonpayment of this Note, and consents to any
and all extensions of time, renewals, waivers, or modifications
that may be granted by Holder with respect to the payment or other
provisions of this Note, or any part thereof, with or without
substitution.

 

10. The
failure of Holder in any one or more instances to insist upon
strict performance of any of the terms and provisions of this Note,
or to exercise any option conferred herein shall not be construed
as a waiver or relinquishment, to any extent, of the right to
assert or rely upon any such terms, provisions or options on any
future occasion.

 

11. This Note
shall be governed by and construed in accordance with the laws of
Nevada, without giving effect to any conflict of laws provisions.
This Note shall bind the successors and assigns of Debtor and shall
inure to benefit of the successors and assigns of
Creditor.

 

12. This Note
constitutes the entire understanding and agreement between the
parties with regard to the subject matters hereof and thereof, and
supersedes and replaces any prior understanding or agreement, oral
or written, relating to such subject matters.

 

IN
WITNESS WHEREOF, Debtor has executed this Note on or as of the day
and year first above written.

 

 

 

Sunshine Biopharma,
Inc.

 

 

By:
/s/ Camille
Sebaaly 

       Camille
Sebaaly, Chief Financial OfficerBlueprint

  Exhibit 10.1

 

EQUITY FINANCING AGREEMENT

 

This
EQUITY FINANCING AGREEMENT (the “Agreement”), dated as
of September 10, 2018 (the “Execution Date”), is
entered into by and between Sunshine Biopharma, Inc., a Colorado
corporation with its principal executive office at 6500
Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R
0A5 (the “Company”), and GHS Investments LLC, a Nevada
limited liability company, with offices at 420 Jericho Turnpike,
Suite 207, Jericho, NY 11753 (the
“Investor”).

 

 

RECITALS:

 

WHEREAS,
the parties desire that, upon the terms and subject to the
conditions contained herein, the Investor shall invest up to Ten
Million Dollars ($10,000,000) (the "Commitment Amount"), from time
to time over the course of thirty six (36) months after an
effective registration of the underlying shares (the
“Contract Period”) to purchase the Company’s
common stock par value $0.001 per share (the “Common
Stock”);

 

WHEREAS, such investments will be made in reliance
upon the exemption from securities registration afforded by Section
4(a)(2) of the Securities Act of 1933, as amended (the
“1933
Act”), Rule 506 of
Regulation D promulgated by the SEC under the 1933 Act, and/or upon
such other exemption from the registration requirements of the 1933
Act as may be available with respect to any or all of the
investments in Common Stock to be made hereunder;
and

 

WHEREAS, contemporaneously with the execution and
delivery of this Agreement, the parties hereto are executing and
delivering a Registration Rights Agreement substantially in the
form attached hereto as Exhibit A
(the “Registration Rights
Agreement”) pursuant to
which the Company has agreed to provide certain registration rights
under the 1933 Act, and the rules and regulations promulgated
thereunder, and applicable state securities
laws.

 

NOW
THEREFORE, in consideration of the foregoing recitals, which shall
be considered an integral part of this Agreement, the covenants and
agreements set forth hereafter, and other good and valuable
consideration, the receipt and sufficiency of which is hereby
acknowledged, the Company and the Investor hereby agree as
follows:

 

SECTION I.

DEFINITIONS

 

For
all purposes of and under this Agreement, the following terms shall
have the respective meanings below, and such meanings shall be
equally applicable to the singular and plural forms of such defined
terms.

 

“1933 Act” shall have the meaning set forth in the
recitals.

 

“1934 Act” shall mean the Securities Exchange Act of
1934, as amended, or any similar federal statute, and the rules and
regulations of the SEC thereunder, all as the same will then be in
effect.

 

“Affiliate” shall have the meaning set forth in
Section
5.7.

 

“Agreement” shall have the meaning set forth in the
preamble.

 

 

1

 

 

“Articles of
Incorporation” shall have
the meaning set forth in Section
4.3.

 

“By-laws” shall have the meaning set forth in
Section
4.3.

 

“Closing” shall have the meaning set forth in
Section
2.4.

 

“Commitment
Fee” shall have the
meaning set forth in Section
2.7.

 

“Closing Date” shall have the meaning set forth in
Section
2.4.

 

“Common Stock” shall have the meaning set forth in the
recitals.

 

“Control” or “Controls” shall have the meaning set forth in
Section
5.7.

 

“Effective
Date” shall mean the date
the SEC declares effective under the 1933 Act the Registration
Statement covering the Securities.

 

“Environmental
Laws” shall have the
meaning set forth in Section
4.13.

 

“Execution
Date” shall have the
meaning set forth in the preamble.

 

“Indemnified
Liabilities” shall have
the meaning set forth in Section
10.

 

“Indemnitees” shall have the meaning set forth in
Section
10.

 

“Indemnitor” shall have the meaning set forth in
Section
10.

 

“Ineffective
Period” shall mean any
period of time that the Registration Statement or any supplemental
registration statement becomes ineffective or unavailable for use
for the sale or resale, as applicable, of any or all of the
Registrable Securities (as defined in the Registration Rights
Agreement) for any reason (or in the event the prospectus under
either of the above is not current and deliverable) during any time
period required under the Registration Rights
Agreement.

 

“Investor” shall have the meaning set forth in the
preamble.

 

“Market
Price” shall mean the
average of the three lowest VWAPs (as defined in section 2.4
herein) of the Company's Common Stock for the ten (10) Trading Days
immediately preceding the Put Notice Date.

 

“Material Adverse
Effect” shall have the
meaning set forth in Section
4.1.

 

“Maximum Common Stock
Issuance” shall have the
meaning set forth in Section
2.5.

 

“Open Period” shall mean the period beginning on and
including the Trading Day immediately following the Effective Date
and ending on the earlier to occur of (i) the date which is thirty
six (36) months from the Effective Date; or (ii) termination of the
Agreement in accordance with Section
8.

 

 

2

 

 

“Pricing
Period” shall mean ten
(10) consecutive trading days preceding the receipt of the
applicable Put Notice.

 

“Principal
Market” shall mean the
New York Stock Exchange, the NYSE Amex, the Nasdaq Capital Market,
the Nasdaq Global Market, the Nasdaq Global Select Market or the
OTC Markets, whichever is the principal market on which the Common
Stock is listed.

 

“Prospectus” shall mean the prospectus, preliminary
prospectus and supplemental prospectus used in connection with the
Registration Statement.

 

“Purchase
Amount” shall mean the
total amount being paid by the Investor on a particular Closing
Date to purchase the Securities.

 

“Purchase
Price” shall mean eighty
one percent (81%) of the Market Price.

 

“Put” shall mean the Company is entitled to
request equity investments (the “Put” or
“Puts”) by the Investor during the Contract Period,
pursuant to which the Company will issue Common Stock to the
Investor with an aggregate Purchase Price equal to the value of the
Put, subject to a price per share calculation based on the Market
Price.

 

“Put Amount” shall mean the total dollar amount
requested by the Company pursuant to an applicable Put. The timing
and amounts of each Put shall be at the discretion of the Company.
The maximum dollar amount of each Put will not exceed two hundred
fifty percent (250%) of the average daily trading dollar volume for
the Company’s Common Stock during the ten (10) trading days
preceding the Put Date. No Put will be made in an amount greater
than three hundred thousand dollars ($300,000). Puts are further
limited to the Investor owning no more than 9.99% of the
outstanding stock of the Company at any given
time.

 

“Put Notice” shall mean a written notice sent to the
Investor by the Company stating the Put Amount in U.S. dollars that
the Company intends to sell to the Investor pursuant to the terms
of the Agreement and stating the current number of Shares issued
and outstanding on such date.

 

“Put Notice
Date” shall mean the
Trading Day, as set forth below, on which the Investor receives a
Put Notice.

 

“Put
Restriction” shall mean a
minimum of ten (10) days following a Put Notice Date. During this
time, the Company shall not be entitled to deliver another Put
Notice.

 

“Put Shares
Due” shall have the
meaning set forth in Section
2.4.

 

“Registered Offering Transaction
Documents” shall mean
this Agreement and the Registration Rights Agreement between the
Company and the Investor as of the date
herewith.

 

“Registration Rights
Agreement” shall have the
meaning set forth in the recitals.

 

“Registration
Statement” means the
registration statement of the Company filed under the 1933 Act
covering the Securities issuable hereunder.

 

“Related
Party” shall have the
meaning set forth in Section
5.7.

 

 

3

 

 

“Resolution” shall have the meaning set forth in
Section
7.5.

 

“SEC” shall mean the U.S. Securities and
Exchange Commission.

 

“SEC
Documents” shall have the
meaning set forth in Section
4.6.

 

“Securities” shall mean the shares of Common Stock
issued pursuant to the terms of this Agreement.

 

“Settlement
Date” shall have the
meaning set forth in Section
6.2.

 

“Shares” shall mean the shares of the
Company’s Common Stock.

 

“Subsidiaries” shall have the meaning set forth in
Section
4.1.

 

“Trading Day” shall mean any day on which the Principal
Market for the Common Stock is open for trading, from the hours of
9:30 am until 4:00 pm.

 

“VWAP” means volume-weighted average
price.

 

“Waiting
Period” shall have the
meaning set forth in Section
2.2.

 

SECTION II

PURCHASE AND SALE OF COMMON STOCK

 

2.1 PURCHASE
AND SALE OF COMMON STOCK.
Subject to the terms and conditions set forth herein, the Company
shall issue and sell to the Investor, and the Investor shall
purchase from the Company, up to that number of Shares having an
aggregate Purchase Price of Ten Million Dollars
($10,000,000).

 

2.2 DELIVERY
OF PUT NOTICES. Subject to the
terms and conditions herein, and from time to time during the Open
Period, the Company may, in its sole discretion, deliver a Put
Notice to the Investor which states the dollar amount (designated
in U.S. Dollars), for which the Company intends to sell Common
Stock to the Investor on a Closing Date (the
“Put”). The Put Notice shall be in the form
attached hereto as Exhibit C
and incorporated herein by reference.
The price of the Put shall be eighty one percent (81%) of the
“Market Price”, which is the average of the three
lowest VWAPs of the Company's Common Stock for the ten (10) Trading
Days immediately preceding the Put Notice Date. During the Open
Period, the Company shall not be entitled to submit a Put Notice
until after the previous Closing has been completed. There will be
a minimum of ten (10) trading days between Put
Notices.

 

2.3 CONDITIONS
TO INVESTOR’S OBLIGATION TO PURCHASE
SHARES. Notwithstanding
anything to the contrary in this Agreement, the Company shall not
be entitled to deliver a Put Notice and the Investor shall not be
obligated to purchase any Shares at a Closing unless each of the
following conditions are satisfied:

 

i.

a
Registration Statement shall have been declared effective and shall
remain effective and available for the resale of all the
Registrable Securities (as defined in the Registration Rights
Agreement) at all times until the Closing with respect to the
subject Put Notice;

 

 

4

 

 

ii.

at
all times during the period beginning on the related Put Notice
Date and ending on and including the related Closing Date, the
Common Stock shall have been listed or quoted for trading on the
Principal Market and shall not have been suspended from trading
thereon for a period of two (2) consecutive Trading Days during the
Open Period and the Company shall not have been notified of any
pending or threatened proceeding or other action to suspend the
trading of the Common Stock;

 

iii.

the
Company has complied with its obligations and is otherwise not in
breach of or in default under, this Agreement, the Registration
Rights Agreement or any other agreement executed between the
parties, which has not been cured prior to delivery of the Put
Notice to the Investor;

 

iv.

no
injunction shall have been issued and remain in force, or action
commenced by a governmental authority which has not been stayed or
abandoned, prohibiting the purchase or the issuance of the
Securities; and

 

v.

the
issuance of the Securities will not violate any shareholder
approval requirements of the Principal Market.

 

If
any of the events described in clauses (i) through (v) above occurs
during a Pricing Period, then the Investor shall have no obligation
to purchase the Put Amount of Common Stock set forth in the
applicable Put Notice.

 

2.4 MECHANICS
OF PURCHASE OF SHARES BY INVESTOR. Subject to the satisfaction of the conditions
set forth in Sections 2.5, 7 and 8 of this Agreement, at the end of
the Pricing Period, the Purchase Price shall be established and the
number of Put Shares shall be delivered for a particular Put. In
the event that (i) the volume-weighted average price (the
“VWAP”) of the Company’s Common Stock for the ten
(10) trading days following a Put Notice (the “Trading
Period”) is less than seventy five percent (75%) of the
Market Price used to determine the Purchase Price in connection
with the Put and (ii) as of the end of such Trading Period, the
Investor holds Shares issued pursuant to such Put Notice (the
“Trading Period Shares”), then the Company shall issue
such additional Shares, on the Trading Day immediately following
the Trading Period, as may be necessary to adjust the Purchase
Price for that portion of the Put represented by the Trading Period
Shares to equal the VWAP during the Trading Period (“Make
Whole Provision”). The Make Whole Provision shall only remain
in effect so long as Convertible Promissory Notes issued by the
Company remain outstanding.

 

The Closing of a Put shall occur upon the first Trading Day
following the receipt and approval by Investor's broker of the Put
Shares, whereby the Company shall have caused the Transfer Agent to
electronically transmit, prior to the applicable Closing Date, the
applicable Put Shares by crediting the account of the Investor's
broker with DTC through its Deposit Withdrawal Agent Commission
("DWAC") system. The Investor shall deliver the Investment Amount
specified in the Put Notice by wire transfer of immediately
available funds to an account designated by the Company if the
aforementioned receipt and approval are confirmed before 9:30 AM
EST or on the following Trading day if receipt and approval by the
Investor's Broker is made after 9:30 AM EST ("Closing Date" or
"Closing"). In addition, on or prior to such Closing Date, each of
the Company and Investor shall deliver to each other all documents,
instruments and writings required to be delivered or reasonably
requested by either of them pursuant to this Agreement in order to
implement and effect the transactions contemplated
herein.

 

 

5

 

 

2.5 OVERALL
LIMIT ON COMMON STOCK ISSUABLE.
Notwithstanding anything contained herein to the contrary, if
during the Open Period the Company becomes listed on an exchange
which limits the number of shares of Common Stock that may be
issued without shareholder approval, then the number of Shares
issuable by the Company and purchasable by the Investor, shall not
exceed that number of the shares of Common Stock that may be
issuable without shareholder approval (the
“Maximum Common Stock
Issuance”). If such
issuance of shares of Common Stock could cause a delisting on the
Principal Market, then the Maximum Common Stock Issuance shall
first be approved by the Company’s shareholders in accordance
with applicable law and the By-laws and the Articles of
Incorporation of the Company, if such issuance of shares of Common
Stock could cause a delisting on the Principal Market. The parties
understand and agree that the Company’s failure to seek or
obtain such shareholder approval shall in no way adversely affect
the validity and due authorization of the issuance and sale of
Securities or the Investor’s obligation in accordance with
the terms and conditions hereof to purchase a number of Shares in
the aggregate up to the Maximum Common Stock Issuance, and that
such approval pertains only to the applicability of the Maximum
Common Stock Issuance limitation provided in this
Section
2.5.

 

2.6 LIMITATION
ON AMOUNT OF OWNERSHIP.
Notwithstanding anything to the contrary in this Agreement, in no
event shall the Investor be entitled to purchase that number of
Shares, which when added to the sum of the number of shares of
Common Stock beneficially owned (as such term is defined under
Section 13(d) and Rule 13d-3 of the 1934 Act), by the Investor,
would exceed 9.99% of the number of shares of Common Stock
outstanding on the Closing Date, as determined in accordance with
Rule 13d-1(j) of the 1934 Act.

 

2.7 COMMITMENT
FEE. The Company shall issue a
promissory note in favor of the Investor in the principal amount of
twenty thousand dollars ($20,000) to offset the transaction costs
incurred by the Investor in connection with this
Agreement.

 

SECTION III

INVESTOR’S REPRESENTATIONS, WARRANTIES AND
COVENANTS

 

The
Investor represents and warrants to the Company, and covenants,
that to the best of the Investor's knowledge:

 

3.1 SOPHISTICATED
INVESTOR. The Investor has, by
reason of its business and financial experience, such knowledge,
sophistication and experience in financial and business matters and
in making investment decisions of this type that it is capable of
(I) evaluating the merits and risks of an investment in the
Securities and making an informed investment decision; (II)
protecting its own interest; and (III) bearing the economic risk of
such investment for an indefinite period of
time.

 

3.2 AUTHORIZATION;
ENFORCEMENT. This Agreement has
been duly and validly authorized, executed and delivered on behalf
of the Investor and is a valid and binding agreement of the
Investor enforceable against the Investor in accordance with its
terms, subject as to enforceability to general principles of equity
and to applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation and other similar laws relating to, or
affecting generally, the enforcement of applicable creditors’
rights and remedies.

 

3.3 SECTION
9 OF THE 1934 ACT. During the
term of this Agreement, the Investor will comply with the
provisions of Section 9 of the 1934 Act, and the rules promulgated
thereunder, with respect to transactions involving the Common
Stock.

 

 

6

 

 

3.4 ACCREDITED
INVESTOR. Investor is an
“Accredited Investor” as that term is defined in Rule
501(a) of Regulation D of the 1933 Act.

 

3.5 NO
CONFLICTS. The execution,
delivery and performance of the Documents by the Investor and the
consummation by the Investor of the transactions contemplated
hereby and thereby will not result in a violation of Partnership
Agreement or other organizational documents of the
Investor.

 

3.6 OPPORTUNITY
TO DISCUSS. The Investor has
received all materials relating to the Company’s business,
finance and operations which it has requested. The Investor has had
an opportunity to discuss the business, management and financial
affairs of the Company with the Company’s
management.

 

3.7 INVESTMENT
PURPOSES. The Investor is
purchasing the Securities for its own account for investment
purposes and not with a view towards distribution and agrees to
resell or otherwise dispose of the Securities solely in accordance
with the registration provisions of the 1933 Act (or pursuant to an
exemption from such registration provisions).

 

3.8 NO
REGISTRATION AS A DEALER. The
Investor is not required to be registered as a “dealer”
under the 1934 Act, either as a result of its execution and
performance of its obligations under this Agreement or
otherwise.

 

3.9 GOOD
STANDING. The Investor is a
limited liability company, duly organized, validly existing and in
good standing in the State of its Nevada.

 

3.10 TAX
LIABILITIES. The Investor
understands that it is liable for its own tax
liabilities.

 

3.11 REGULATION
M. The Investor will comply
with Regulation M under the 1934 Act, if
applicable.

 

3.12 NO
SHORT SALES. No short sales
shall be permitted by the Investor or its affiliates during the
period commencing on the Execution Date and continuing through the
termination of this Agreement.

 

SECTION IV

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

Except
as set forth in the Schedules attached hereto, or as disclosed on
the Company’s SEC Documents, the Company represents and
warrants to the Investor that:

 

4.1 ORGANIZATION
AND QUALIFICATION. The Company
is a corporation duly organized and validly existing in good
standing under the laws of the State of Colorado and has the
requisite corporate power and authorization to own its properties
and to carry on its business as now being conducted. Both the
Company and the companies it owns or controls
(“Subsidiaries”) are duly qualified to do business and are
in good standing in every jurisdiction in which its ownership of
property or the nature of the business conducted by it makes such
qualification necessary, except to the extent that the failure to
be so qualified or be in good standing would not have a Material
Adverse Effect. As used in this Agreement,
“Material Adverse
Effect” means a change,
event, circumstance, effect or state of facts that has had or is
reasonably likely to have, a material adverse effect on the
business, properties, assets, operations, results of operations,
financial condition or prospects of the Company and its
Subsidiaries, if any, taken as a whole, or on the transactions
contemplated hereby or by the agreements and instruments to be
entered into in connection herewith, or on the authority or ability
of the Company to perform its obligations under the Registered
offering Transaction Documents.

 

 

7

 

 

4.2 AUTHORIZATION;
ENFORCEMENT; COMPLIANCE WITH OTHER INSTRUMENTS.

 

i.

The Company has the requisite corporate power and
authority to enter into and perform this Investment Agreement and
the Registration Rights Agreement (collectively, the
“Registered Offering Transaction
Documents”), and to issue
the Securities in accordance with the terms hereof and
thereof.

 

ii.

The
execution and delivery of the Registered Offering Transaction
Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby, including without
limitation the issuance of the Securities pursuant to this
Agreement, have been duly and validly authorized by the
Company’s Board of Directors and no further consent or
authorization is required by the Company, its Board of Directors,
or its shareholders.

 

iii.

The
Registered Offering Transaction Documents have been duly and
validly executed and delivered by the Company.

 

iv.

The
Registered Offering Transaction Documents constitute the valid and
binding obligations of the Company enforceable against the Company
in accordance with their terms, except as such enforceability may
be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or
similar laws relating to, or affecting generally, the enforcement
of creditors’ rights and remedies.

 

4.3 CAPITALIZATION.
As of August 17, 2018, the authorized capital stock of the Company
consists of 3,000,000,000 shares of the Common Stock, par value
$0.001 per share, of which as of the same date1,179,237,384 shares
are issued and outstanding. All of such outstanding shares have
been, or upon issuance will be, validly issued and are fully paid
and nonassessable.

 

Except as disclosed in the Company’s publicly available
filings with the SEC:

 

i.

no
shares of the Company’s capital stock are subject to
preemptive rights or any other similar rights or any liens or
encumbrances suffered or permitted by the Company;

 

ii.

there
are no outstanding debt securities;

 

iii.

there
are no outstanding shares of capital stock, options, warrants,
scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights
convertible into, any shares of capital stock of the Company or any
of its Subsidiaries, or contracts, commitments, understandings or
arrangements by which the Company or any of its Subsidiaries is or
may become bound to issue additional shares of capital stock of the
Company or any of its Subsidiaries or options, warrants, scrip,
rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities or rights convertible into,
any shares of capital stock of the Company or any of its
Subsidiaries;

 

 

 

8

 

 

iv.

there
are no agreements or arrangements under which the Company or any of
its Subsidiaries is obligated to register the sale of any of their
securities under the 1933 Act (except the Registration Rights
Agreement);

 

v.

there
are no outstanding securities of the Company or any of its
Subsidiaries which contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or
arrangements by which the Company or any of its Subsidiaries is or
may become bound to redeem a security of the Company or any of its
Subsidiaries;

 

vi.

there
are no securities or instruments containing anti-dilution or
similar provisions that will be triggered by the issuance of the
Securities as described in this Agreement;

 

vii.

the
Company does not have any stock appreciation rights or
“phantom stock” plans or agreements or any similar plan
or agreement; and

 

viii.

there
is no dispute as to the classification of any shares of the
Company’s capital stock.

 

The Company has furnished to the Investor, or the Investor has had
access through EDGAR to, true and correct copies of the
Company’s Articles of Incorporation, as in effect on the date
hereof (the “Articles of
Incorporation”), and the
Company’s By-laws, as in effect on the date hereof (the
“By-laws”), and the terms of all securities
convertible into or exercisable for Common Stock and the material
rights of the holders thereof in respect
thereto.

 

4.4 ISSUANCE
OF SHARES. The Company has
reserved the amount of Shares included in the Company’s
registration statement for issuance pursuant to the Registered
Offering Transaction Documents, which have been duly authorized and
reserved (subject to adjustment pursuant to the Company’s
covenant set forth in Section 5.5
below) pursuant to this Agreement.
Upon issuance in accordance with this Agreement, the Securities
will be validly issued, fully paid for and non-assessable and free
from all taxes, liens and charges with respect to the issuance
thereof. In the event the Company cannot register a sufficient
number of Shares for issuance pursuant to this Agreement, the
Company will use its best efforts to authorize and reserve for
issuance the number of Shares required for the Company to perform
its obligations hereunder as soon as reasonably
practicable.

 

 

 

9

 

 

4.5 NO
CONFLICTS. The execution,
delivery and performance of the Registered Offering Transaction
Documents by the Company and the consummation by the Company of the
transactions contemplated hereby and thereby will not (i) result in
a violation of the Articles of Incorporation, any Certificate of
Designations, Preferences and Rights of any outstanding series of
preferred stock of the Company or the By-laws; or (ii) conflict
with, or constitute a material default (or an event which with
notice or lapse of time or both would become a material default)
under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any material agreement, contract,
indenture mortgage, indebtedness or instrument to which the Company
or any of its Subsidiaries is a party, or to the Company’s
knowledge result in a violation of any law, rule, regulation,
order, judgment or decree (including United States federal and
state securities laws and regulations and the rules and regulations
of the Principal Market or principal securities exchange or trading
market on which the Common Stock is traded or listed) applicable to
the Company or any of its Subsidiaries or by which any property or
asset of the Company or any of its Subsidiaries is bound or
affected. Neither the Company nor its Subsidiaries is in violation
of any term of, or in default under, the Articles of Incorporation,
any Certificate of Designations, Preferences and Rights of any
outstanding series of preferred stock of the Company or the By-laws
or their organizational charter or by-laws, respectively, or any
contract, agreement, mortgage, indebtedness, indenture, instrument,
judgment, decree or order or any statute, rule or regulation
applicable to the Company or its Subsidiaries, except for possible
conflicts, defaults, terminations, amendments, accelerations,
cancellations and violations that would not individually or in the
aggregate have or constitute a Material Adverse Effect. The
business of the Company and its Subsidiaries is not being
conducted, and shall not be conducted, in violation of any law,
statute, ordinance, rule, order or regulation of any governmental
authority or agency, regulatory or self-regulatory agency, or
court, except for possible violations the sanctions for which
either individually or in the aggregate would not have a Material
Adverse Effect. Except as specifically contemplated by this
Agreement and as required under the 1933 Act or any securities laws
of any states, to the Company’s knowledge, the Company is not
required to obtain any consent, authorization, permit or order of,
or make any filing or registration (except the filing of a
registration statement as outlined in the Registration Rights
Agreement between the parties) with, any court, governmental
authority or agency, regulatory or self-regulatory agency or other
third party in order for it to execute, deliver or perform any of
its obligations under, or contemplated by, the Registered Offering
Transaction Documents in accordance with the terms hereof or
thereof. All consents, authorizations, permits, orders, filings and
registrations which the Company is required to obtain pursuant to
the preceding sentence have been obtained or effected on or prior
to the date hereof and are in full force and effect as of the date
hereof. The Company and its Subsidiaries are unaware of any facts
or circumstances which might give rise to any of the foregoing. The
Company is not, and will not be, in violation of the listing
requirements of the Principal Market as in effect on the date
hereof and on each of the Closing Dates and is not aware of any
facts which would reasonably lead to delisting of the Common Stock
by the Principal Market in the foreseeable
future.

 

 

 

10

 

 

4.6  SEC
DOCUMENTS; FINANCIAL STATEMENTS. As of the date hereof, the Company has filed all
reports, schedules, forms, statements and other documents required
to be filed by it with the SEC pursuant to the reporting
requirements of the 1934 Act (all of the foregoing filed prior to
the date hereof and all exhibits included therein and financial
statements and schedules thereto and documents incorporated by
reference therein, and amendments thereto, being hereinafter
referred to as the “SEC
Documents”). The Company
has delivered to the Investor or its representatives, or they have
had access through EDGAR to, true and complete copies of the SEC
Documents. As of their respective filing dates, the SEC Documents
complied in all material respects with the requirements of the 1934
Act and the rules and regulations of the SEC promulgated thereunder
applicable to the SEC Documents, and none of the SEC Documents, at
the time they were filed with the SEC or the time they were
amended, if amended, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated
therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading. As of
their respective dates, the financial statements of the Company
included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and the published
rules and regulations of the SEC with respect thereto. Such
financial statements have been prepared in accordance with
generally accepted accounting principles, by a firm that is a
member of the Public Companies Accounting Oversight Board
(“PCAOB”) consistently applied, during the periods
involved (except (i) as may be otherwise indicated in such
financial statements or the notes thereto, or (ii) in the case of
unaudited interim statements, to the extent they may exclude
footnotes or may be condensed or summary statements) and fairly
present in all material respects the financial position of the
Company as of the dates thereof and the results of its operations
and cash flows for the periods then ended (subject, in the case of
unaudited statements, to normal year-end audit adjustments). No
other written information provided by or on behalf of the Company
to the Investor which is not included in the SEC Documents,
including, without limitation, information referred to in
Section
4.3of this Agreement, contains
any untrue statement of a material fact or omits to state any
material fact necessary to make the statements therein, in the
light of the circumstance under which they are or were made, not
misleading. Neither the Company nor any of its Subsidiaries or any
of their officers, directors, employees or agents have provided the
Investor with any material, nonpublic information which was not
publicly disclosed prior to the date hereof and any material,
nonpublic information provided to the Investor by the Company or
its Subsidiaries or any of their officers, directors, employees or
agents prior to any Closing Date shall be publicly disclosed by the
Company prior to such Closing Date.

 

4.7 ABSENCE
OF CERTAIN CHANGES. Except as
otherwise set forth in the SEC Documents, the Company does not
intend to change the business operations of the Company in any
material way. The Company has not taken any steps, and does not
currently expect to take any steps, to seek protection pursuant to
any bankruptcy law nor does the Company or its Subsidiaries have
any knowledge or reason to believe that its creditors intend to
initiate involuntary bankruptcy proceedings.

 

4.8 ABSENCE
OF LITIGATION AND/OR REGULATORY PROCEEDINGS. Except as set forth in the SEC Documents, there
is no action, suit, proceeding, inquiry or investigation before or
by any court, public board, government agency, self-regulatory
organization or body pending or, to the knowledge of the executive
officers of Company or any of its Subsidiaries, threatened against
or affecting the Company, the Common Stock or any of the
Company’s Subsidiaries or any of the Company’s or the
Company’s Subsidiaries’ officers or directors in their
capacities as such, in which an adverse decision could have a
Material Adverse Effect.

 

 

 

11

 

 

4.9 ACKNOWLEDGMENT
REGARDING INVESTOR’S PURCHASE OF SHARES. The Company acknowledges and agrees that the
Investor is acting solely in the capacity of an arm’s length
Investor with respect to the Registered Offering Transaction
Documents and the transactions contemplated hereby and thereby. The
Company further acknowledges that the Investor is not acting as a
financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Registered Offering Transaction
Documents and the transactions contemplated hereby and thereby and
any advice given by the Investor or any of its respective
representatives or agents in connection with the Registered
Offering Transaction Documents and the transactions contemplated
hereby and thereby is merely incidental to the Investor’s
purchase of the Securities, and is not being relied on by the
Company. The Company further represents to the Investor that the
Company’s decision to enter into the Registered Offering
Transaction Documents has been based solely on the independent
evaluation by the Company and its
representatives.

 

4.10 NO
UNDISCLOSED EVENTS, LIABILITIES, DEVELOPMENTS OR
CIRCUMSTANCES. Except as set
forth in the SEC Documents, as of the date hereof, no event,
liability, development or circumstance has occurred or exists, or
to the Company’s knowledge is contemplated to occur, with
respect to the Company or its Subsidiaries or their respective
business, properties, assets, prospects, operations or financial
condition, that would be required to be disclosed by the Company
under applicable securities laws on a registration statement filed
with the SEC relating to an issuance and sale by the Company of its
Common Stock and which has not been publicly
announced.

 

4.11 EMPLOYEE
RELATIONS. Neither the Company
nor any of its Subsidiaries is involved in any union labor dispute
nor, to the knowledge of the Company or any of its Subsidiaries, is
any such dispute threatened. Neither the Company nor any of its
Subsidiaries is a party to a collective bargaining agreement, and
the Company and its Subsidiaries believe that relations with their
employees are good. No executive officer (as defined in Rule 501(f)
of the 1933 Act) has notified the Company that such officer intends
to leave the Company’s employ or otherwise terminate such
officer’s employment with the Company.

 

4.12 INTELLECTUAL
PROPERTY RIGHTS. The Company
and its Subsidiaries own or possess adequate rights or licenses to
use all trademarks, trade names, service marks, service mark
registrations, service names, patents, patent rights, copyrights,
inventions, licenses, approvals, governmental authorizations, trade
secrets and rights necessary to conduct their respective businesses
as now conducted. Except as set forth in the SEC Documents, none of
the Company’s trademarks, trade names, service marks, service
mark registrations, service names, patents, patent rights,
copyrights, inventions, licenses, approvals, government
authorizations, trade secrets or other intellectual property rights
necessary to conduct its business as now or as proposed to be
conducted have expired or terminated, or are expected to expire or
terminate within two (2) years from the date of this Agreement. The
Company and its Subsidiaries do not have any knowledge of any
infringement by the Company or its Subsidiaries of trademark, trade
name rights, patents, patent rights, copyrights, inventions,
licenses, service names, service marks, service mark registrations,
trade secret or other similar rights of others, or of any such
development of similar or identical trade secrets or technical
information by others and, except as set forth in the SEC
Documents, there is no claim, action or proceeding being made or
brought against, or to the Company’s knowledge, being
threatened against, the Company or its Subsidiaries regarding
trademark, trade name, patents, patent rights, invention,
copyright, license, service names, service marks, service mark
registrations, trade secret or other infringement; and the Company
and its Subsidiaries are unaware of any facts or circumstances
which might give rise to any of the foregoing. The Company and its
Subsidiaries have taken commercially reasonable security measures
to protect the secrecy, confidentiality and value of all of their
intellectual properties.

 

 

12

 

 

4.13 ENVIRONMENTAL
LAWS. The Company and its
Subsidiaries (i) are, to the knowledge of the management and
directors of the Company and its Subsidiaries, in compliance with
any and all applicable foreign, federal, state and local laws and
regulations relating to the protection of human health and safety,
the environment or hazardous or toxic substances or wastes,
pollutants or contaminants (“Environmental
Laws”); (ii) have, to the
knowledge of the management and directors of the Company, received
all permits, licenses or other approvals required of them under
applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance, to the knowledge of the
management and directors of the Company, with all terms and
conditions of any such permit, license or approval where, in each
of the three (3) foregoing cases, the failure to so comply would
have, individually or in the aggregate, a Material Adverse
Effect.

 

4.14 TITLE.
The Company and its Subsidiaries have good and marketable title to
all personal property owned by them which is material to the
business of the Company and its Subsidiaries, in each case free and
clear of all liens, encumbrances and defects except such as are
described in the SEC Documents or such as do not materially affect
the value of such property and do not interfere with the use made
and proposed to be made of such property by the Company or any of
its Subsidiaries. Any real property and facilities held under lease
by the Company or any of its Subsidiaries are held by them under
valid, subsisting and enforceable leases with such exceptions as
are not material and do not interfere with the use made and
proposed to be made of such property and buildings by the Company
and its Subsidiaries.

 

4.15 INSURANCE.
Each of the Company’s Subsidiaries are insured by insurers of
recognized financial responsibility against such losses and risks
and in such amounts as management of the Company reasonably
believes to be prudent and customary in the businesses in which the
Company and its Subsidiaries are engaged. Neither the Company nor
any of its Subsidiaries has been refused any insurance coverage
sought or applied for and neither the Company nor its Subsidiaries
has any reason to believe that it will not be able to renew its
existing insurance coverage as and when such coverage expires or to
obtain similar coverage from similar insurers as may be necessary
to continue its business at a cost that would not have a Material
Adverse Effect.

 

4.16 REGULATORY
PERMITS. The Company and its
Subsidiaries have in full force and effect all certificates,
approvals, authorizations and permits from the appropriate federal,
state, local or foreign regulatory authorities and comparable
foreign regulatory agencies, necessary to own, lease or operate
their respective properties and assets and conduct their respective
businesses, and neither the Company nor any such Subsidiary has
received any notice of proceedings relating to the revocation or
modification of any such certificate, approval, authorization or
permit, except for such certificates, approvals, authorizations or
permits which if not obtained, or such revocations or modifications
which, would not have a Material Adverse
Effect.

 

4.17 INTERNAL
ACCOUNTING CONTROLS. Except as
otherwise set forth in the SEC Documents, the Company and each of
its Subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i) transactions
are executed in accordance with management’s general or
specific authorizations; (ii) transactions are recorded as
necessary to permit preparation of financial statements in
conformity with generally accepted accounting principles by a firm
with membership to the PCAOB and to maintain asset accountability;
(iii) access to assets is permitted only in accordance with
management’s general or specific authorization; and (iv) the
recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with
respect to any differences. The Company’s management has
determined that the Company’s internal accounting controls
were not effective as of the date of this Agreement as further
described in the SEC Documents.

 

 

13

 

 

4.18 NO
MATERIALLY ADVERSE CONTRACTS, ETC. Neither the Company nor any of its Subsidiaries
is subject to any charter, corporate or other legal restriction, or
any judgment, decree, order, rule or regulation which in the
judgment of the Company’s officers has or is expected in the
future to have a Material Adverse Effect. Neither the Company nor
any of its Subsidiaries is a party to any contract or agreement
which in the judgment of the Company’s officers has or is
expected to have a Material Adverse Effect.

 

4.19 TAX
STATUS. The Company and each of
its Subsidiaries has made or filed all United States federal and
state income and all other tax returns, reports and declarations
required by any jurisdiction to which it is subject (unless and
only to the extent that the Company and each of its Subsidiaries
has set aside on its books provisions reasonably adequate for the
payment of all unpaid and unreported taxes) and has paid all taxes
and other governmental assessments and charges that are material in
amount, shown or determined to be due on such returns, reports and
declarations, except those being contested in good faith and has
set aside on its books provision reasonably adequate for the
payment of all taxes for periods subsequent to the periods to which
such returns, reports or declarations apply. There are no unpaid
taxes in any material amount claimed to be due by the taxing
authority of any jurisdiction, and the officers of the Company know
of no basis for any such claim.

 

4.20 CERTAIN
TRANSACTIONS. Except as set
forth in the SEC Documents filed at least ten (10) days prior to
the date hereof and except for arm’s length transactions
pursuant to which the Company makes payments in the ordinary course
of business upon terms no less favorable than the Company could
obtain from disinterested third parties, none of the officers,
directors, or employees of the Company is presently a party to any
transaction with the Company or any of its Subsidiaries (other than
for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the
furnishing of services to or by, providing for rental of real or
personal property to or from, or otherwise requiring payments to or
from any officer, director or such employee or, to the knowledge of
the Company, any corporation, partnership, trust or other entity in
which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee or partner, such that
disclosure would be required in the SEC
Documents.

 

4.21 DILUTIVE
EFFECT. The Company understands
and acknowledges that the number of shares of Common Stock issuable
upon purchases pursuant to this Agreement will increase in certain
circumstances including, but not necessarily limited to, the
circumstance wherein the trading price of the Common Stock declines
during the period between the Effective Date and the end of the
Open Period. The Company’s executive officers and directors
have studied and fully understand the nature of the transactions
contemplated by this Agreement and recognize that they have a
potential dilutive effect on the shareholders of the Company. The
Board of Directors of the Company has concluded, in its good faith
business judgment, and with full understanding of the implications,
that such issuance is in the best interests of the Company. The
Company specifically acknowledges that, subject to such limitations
as are expressly set forth in the Registered Offering Transaction
Documents, its obligation to issue shares of Common Stock upon
purchases pursuant to this Agreement is absolute and unconditional
regardless of the dilutive effect that such issuance may have on
the ownership interests of other shareholders of the
Company.

 

4.22 NO
GENERAL SOLICITATION. Neither
the Company, nor any of its affiliates, nor any person acting on
its behalf, has engaged in any form of general solicitation or
general advertising (within the meaning of Regulation D) in
connection with the offer or sale of the Common Stock to be offered
as set forth in this Agreement.

 

 

14

 

 

4.23 NO
BROKERS, FINDERS OR FINANCIAL ADVISORY FEES OR
COMMISSIONS. No brokers,
finders or financial advisory fees or commissions will be payable
by the Company, its agents or Subsidiaries, with respect to the
transactions contemplated by this Agreement.

 

4.24 EXCLUSIVITY.
The Company shall not pursue a similar Equity Financing transaction
with any other party unless and until good faith negotiations have
terminated between the Investor and the Company or until such time
as the registration statement has been declared effective by the
SEC.

 

SECTION V

COVENANTS OF THE COMPANY

 

5.1 BEST
EFFORTS. The Company shall use
all commercially reasonable efforts to timely satisfy each of the
conditions set forth in Section 7
of this Agreement.

 

5.2 REPORTING
STATUS. Until one of the
following occurs, the Company shall file all reports required to be
filed with the SEC pursuant to the 1934 Act, and the Company shall
not terminate its status, or take an action or fail to take any
action, which would terminate its status as a reporting company
under the 1934 Act: (i) this Agreement terminates pursuant
to Section 8
and the Investor has the right to sell
all of the Securities without restrictions pursuant to Rule 144
promulgated under the 1933 Act, or such other exemption, or (ii)
the date on which the Investor has sold all the Securities and this
Agreement has been terminated pursuant to Section
8.

 

5.3 USE
OF PROCEEDS. The Company will
use the proceeds from the sale of the Shares (excluding amounts
paid by the Company for fees as set forth in the Registered
Offering Transaction Documents) for general corporate and working
capital purposes and acquisitions or assets, businesses or
operations or for other purposes that the Board of Directors, in
good faith deem to be in the best interest of the
Company.

 

5.4 FINANCIAL
INFORMATION. During the Open
Period, the Company agrees to make available to the Investor via
EDGAR or other electronic means the following documents and
information on the forms set forth: (i) within five (5) Trading
Days after the filing thereof with the SEC, a copy of its Annual
Reports on Form 10-K, its Quarterly Reports on Form 10-Q, any
Current Reports on Form 8-K and any Registration Statements or
amendments filed pursuant to the 1933 Act; (ii) copies of any
notices and other information made available or given to the
shareholders of the Company generally, contemporaneously with the
making available or giving thereof to the shareholders; and (iii)
within two (2) calendar days of filing or delivery thereof, copies
of all documents filed with, and all correspondence sent to, the
Principal Market, any securities exchange or market, or the
Financial Industry Regulatory Association, unless such information
is material nonpublic information.

 

5.5 RESERVATION
OF SHARES. The Company shall
take all action necessary to at all times have authorized, and
reserved the amount of Shares included in the Company’s
registration statement for issuance pursuant to the Registered
Offering Transaction Documents. In the event that the Company
determines that it does not have a sufficient number of authorized
shares of Common Stock to reserve and keep available for issuance
as described in this Section
5.5, the Company shall use all
commercially reasonable efforts to increase the number of
authorized shares of Common Stock by seeking shareholder approval
for the authorization of such additional
shares.

 

 

 

15

 

 

5.6 LISTING.
The Company shall promptly secure and maintain the listing of all
of the Registrable Securities (as defined in the Registration
Rights Agreement) on the Principal Market and each other national
securities exchange and automated quotation system, if any, upon
which shares of Common Stock are then listed (subject to official
notice of issuance) and shall maintain, such listing of all
Registrable Securities from time to time issuable under the terms
of the Registered Offering Transaction Documents. Neither the
Company nor any of its Subsidiaries shall take any action which
would be reasonably expected to result in the delisting or
suspension of the Common Stock on the Principal Market (excluding
suspensions of not more than one (1) Trading Day resulting from
business announcements by the Company). The Company shall promptly
provide to the Investor copies of any notices it receives from the
Principal Market regarding the continued eligibility of the Common
Stock for listing on such automated quotation system or securities
exchange. The Company shall pay all fees and expenses in connection
with satisfying its obligations under this Section
5.6.

 

5.7 TRANSACTIONS
WITH AFFILIATES. The Company
shall not, and shall cause each of its Subsidiaries not to, enter
into, amend, modify or supplement, or permit any Subsidiary to
enter into, amend, modify or supplement, any agreement,
transaction, commitment or arrangement with any of its or any
Subsidiary’s officers, directors, persons who were officers
or directors at any time during the previous two (2) years,
shareholders who beneficially own 5% or more of the Common Stock,
or Affiliates or with any individual related by blood, marriage or
adoption to any such individual or with any entity in which any
such entity or individual owns a 5% or more beneficial interest
(each a “Related
Party”), except for (i)
customary employment arrangements and benefit programs on
reasonable terms, (ii) any agreement, transaction, commitment or
arrangement on an arms-length basis on terms no less favorable than
terms which would have been obtainable from a disinterested third
party other than such Related Party, or (iii) any agreement,
transaction, commitment or arrangement which is approved by a
majority of the disinterested directors of the Company. For
purposes hereof, any director who is also an officer of the Company
or any Subsidiary of the Company shall not be a disinterested
director with respect to any such agreement, transaction,
commitment or arrangement. “Affiliate” for purposes hereof means, with respect to
any person or entity, another person or entity that, directly or
indirectly, (i) has a 5% or more equity interest in that person or
entity, (ii) has 5% or more common ownership with that person or
entity, (iii) controls that person or entity, or (iv) is under
common control with that person or entity.
“Control” or “Controls” for purposes hereof means that a person or
entity has the power, directly or indirectly, to conduct or govern
the policies of another person or entity.

 

5.8 FILING
OF FORM 8-K. On or before the
date which is four (4) Trading Days after the Execution Date, the
Company shall file a Current Report on Form 8-K with the SEC
describing the terms of the transaction contemplated by the
Registered Offering Transaction Documents in the form required by
the 1934 Act, if such filing is required.

 

5.9 CORPORATE
EXISTENCE. The Company shall
use all commercially reasonable efforts to preserve and continue
the corporate existence of the Company.

 

 

 

16

 

 

5.10 NOTICE
OF CERTAIN EVENTS AFFECTING REGISTRATION; SUSPENSION OF RIGHT TO
MAKE A PUT. The Company shall
promptly notify the Investor upon the occurrence of any of the
following events in respect of a Registration Statement or related
prospectus in respect of an offering of the Securities: (i) receipt
of any request for additional information by the SEC or any other
federal or state governmental authority during the period of
effectiveness of the Registration Statement for amendments or
supplements to the Registration Statement or related prospectus;
(ii) the issuance by the SEC or any other federal or state
governmental authority of any stop order suspending the
effectiveness of any Registration Statement or the initiation of
any proceedings for that purpose; (iii) receipt of any notification
with respect to the suspension of the qualification or exemption
from qualification of any of the Securities for sale in any
jurisdiction or the initiation or notice of any proceeding for such
purpose; (iv) the happening of any event that makes any statement
made in such Registration Statement or related prospectus or any
document incorporated or deemed to be incorporated therein by
reference untrue in any material respect or that requires the
making of any changes in the Registration Statement, related
prospectus or documents so that, in the case of a Registration
Statement, it will not contain any untrue statement of a material
fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading,
and that in the case of the related prospectus, it will not contain
any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under
which they were made, not misleading; and (v) the Company’s
reasonable determination that a post-effective amendment or
supplement to the Registration Statement would be appropriate, and
the Company shall promptly make available to Investor any such
supplement or amendment to the related prospectus. The Company
shall not deliver to Investor any Put Notice during the
continuation of any of the foregoing events in this
Section
5.10.

 

5.11 TRANSFER
AGENT. The Company shall
deliver instructions to its transfer agent to issue Shares to the
Investor Pursuant to the Transactions contemplated
herein.

 

5.12 ACKNOWLEDGEMENT
OF TERMS. The Company hereby
represents and warrants to the Investor that: (i) it is voluntarily
entering into this Agreement of its own freewill, (ii) it is not
entering this Agreement under economic duress, (iii) the terms of
this Agreement are reasonable and fair to the Company, and (iv) the
Company has had independent legal counsel of its own choosing
review this Agreement, advise the Company with respect to this
Agreement, and represent the Company in connection with this
Agreement.

 

 

SECTION VI

CONDITIONS OF THE COMPANY’S OBLIGATION TO SELL

 

The
obligation hereunder of the Company to issue and sell the
Securities to the Investor is further subject to the satisfaction,
at or before each Closing Date, of each of the following conditions
set forth below. These conditions are for the Company’s sole
benefit and may be waived by the Company at any time in its sole
discretion.

 

6.1 The
Investor shall have executed this Agreement and the Registration
Rights Agreement and delivered the same to the
Company.

 

6.2 The
Investor shall have delivered to the Company the Purchase Price for
the Securities being purchased by the Investor.

 

 

17

 

 

6.3 No
statute, rule, regulation, executive order, decree, ruling or
injunction shall have been enacted, entered, promulgated or
endorsed by any court or governmental authority of competent
jurisdiction which prohibits the consummation of any of the
transactions contemplated by this Agreement.

 

SECTION VII

FURTHER CONDITIONS OF THE INVESTOR’S OBLIGATION TO
PURCHASE

 

The
obligation of the Investor hereunder to purchase Securities is
subject to the satisfaction, on or before each Closing Date, of
each of the following conditions set forth below.

 

7.1 The
Company shall have executed the Registered Offering Transaction
Documents and delivered the same to the Investor.

 

7.2 The
representations and warranties of the Company shall be true and
correct as of the date when made and as of the applicable Closing
Date as though made at that time and the Company shall have
performed, satisfied and complied with the covenants, agreements
and conditions required by the Registered Offering Transaction
Documents to be performed, satisfied or complied with by the
Company on or before such Closing Date. The Investor may request an
update as of such Closing Date regarding the representation
contained in Section
4.3.

 

7.3 The
Company shall have executed and delivered to the Investor the
certificates representing, or have executed electronic book-entry
transfer of, the Securities (in such denominations as the Investor
shall request) being purchased by the Investor at such
Closing.

 

7.4 The
Board of Directors of the Company shall have adopted resolutions
consistent with Section 4.2(ii)
(the “Resolutions”) and such Resolutions shall not have been
amended or rescinded prior to such Closing
Date.

 

7.5 No
statute, rule, regulation, executive order, decree, ruling or
injunction shall have been enacted, entered, promulgated or
endorsed by any court or governmental authority of competent
jurisdiction which prohibits the consummation of any of the
transactions contemplated by this Agreement.

 

7.6 Within
thirty (30) days after the Agreement is executed, the Company
agrees to use its best efforts to file with the SEC a registration
statement covering the shares of stock underlying the Equity
Financing contemplated herein. Such registration statement shall
conform to the requirements of the rules and regulations of the SEC
and the terms and conditions of Equity Financing this agreement as
expressed in the registration statement shall be reviewed and
approved by the Investor. The Company will take any and all steps
necessary to have its registration statement declared effective by
the SEC within 30 days but no more than 90 days after the Company
has filed its registration statement. Such registration Statement
shall conform to the requirements of the rules and regulations of
the SEC and the terms and conditions of the equity financing Equity
Financing as expressed in the Registration Statement and shall be
reviewed and approved by the Investor. The Registration Statement
shall be effective on each Closing Date and no stop order
suspending the effectiveness of the Registration statement shall be
in effect or to the Company’s knowledge shall be pending or
threatened. Furthermore, on each Closing Date (I) neither the
Company nor the Investor shall have received notice that the SEC
has issued or intends to issue a stop order with respect to such
Registration Statement or that the SEC otherwise has suspended or
withdrawn the effectiveness of such Registration Statement, either
temporarily or permanently, or intends or has threatened to do so
(unless the SEC’s concerns have been addressed), and (II) no
other suspension of the use or withdrawal of the effectiveness of
such Registration Statement or related prospectus shall
exist.

 

 

 

18

 

 

7.7 At
the time of each Closing, the Registration Statement (including
information or documents incorporated by reference therein) and any
amendments or supplements thereto shall not contain any untrue
statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements
therein not misleading or which would require public disclosure or
an update supplement to the prospectus.

 

7.8 If
applicable, the shareholders of the Company shall have approved the
issuance of any Shares in excess of the Maximum Common Stock
Issuance in accordance with Section 2.5
or the Company shall have obtained
appropriate approval pursuant to the requirements of applicable
state and federal laws and the Company’s Articles of
Incorporation and By-laws.

 

7.9 The
conditions to such Closing set forth in Section 2.3
shall have been satisfied on or before
such Closing Date.

 

7.10 The
Company shall have certified to the Investor the number of Shares
of Common Stock outstanding when a Put Notice is given to the
Investor. The Company’s delivery of a Put Notice to the
Investor constitutes the Company’s certification of the
existence of the necessary number of shares of Common Stock
reserved for issuance.

 

SECTION VIII

TERMINATION

 

This
Agreement shall terminate upon any of the following
events:

 

8.1 when
the Investor has purchased an aggregate of Ten Million Dollars
($10,000,000) in the Common Stock of the Company pursuant to this
Agreement; or

 

8.2 on
the date which is thirty six (36) months after the Effective Date;
or

 

8.3 at
such time that the Registration Statement is no longer in
effect.

 

Any
and all shares, or penalties, if any, due under this Agreement
shall be immediately payable and due upon termination of this
Agreement.

 

SECTION IX

SUSPENSION

 

This
Agreement shall be suspended upon any of the following events, and
shall remain suspended until such event is rectified:

 

i.

The
trading of the Common Stock is suspended by the SEC, the Principal
Market or FINRA for a period of two (2) consecutive Trading Days
during the Open Period; or

 

ii.

The
Common Stock ceases to be quoted, listed or traded on the Principal
Market or the Registration Statement is no longer effective (except
as permitted hereunder). Immediately upon the occurrence of one of
the above-described events, the Company shall send written notice
of such event to the Investor.

 

 

 

19

 

 

SECTION X

INDEMNIFICATION

 

In
consideration of the parties mutual obligations set forth in the
Transaction Documents, the Company ( the “Indemnitor”) shall defend,
protect, indemnify and hold harmless the Investor and all of the
investor’s shareholders, officers, directors, employees,
counsel, and direct or indirect investors and any of the foregoing
person’s agents or other representatives (including, without
limitation, those retained in connection with the transactions
contemplated by this Agreement) (collectively, the
“Indemnitees”)
from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages,
and reasonable expenses in connection therewith (irrespective of
whether any such Indemnitee is a party to the action for which
indemnification hereunder is sought), and including reasonable
attorneys’ fees and disbursements (the “Indemnified Liabilities”),
incurred by any Indemnitee as a result of, or arising out of, or
relating to (I) any misrepresentation or breach of any
representation or warranty made by the Indemnitor or any other
certificate, instrument or document contemplated hereby or thereby;
(II) any breach of any covenant, agreement or obligation of the
Indemnitor contained in the Registered Offering Transaction
Documents or any other certificate, instrument or document
contemplated hereby or thereby; or (III) any cause of action, suit
or claim brought or made against such Indemnitee by a third party
and arising out of or resulting from the execution, delivery,
performance or enforcement of the Registered Offering Transaction
Documents or any other certificate, instrument or document
contemplated hereby or thereby, except insofar as any such
misrepresentation, breach or any untrue statement, alleged untrue
statement, omission or alleged omission is made in reliance upon
and in conformity with information furnished to Indemnitor which is
specifically intended for use in the preparation of any such
Registration Statement, preliminary prospectus, prospectus or
amendments to the prospectus. To the extent that the foregoing
undertaking by the Indemnitor may be unenforceable for any reason,
the Indemnitor shall make the maximum contribution to the payment
and satisfaction of each of the Indemnified Liabilities which is
permissible under applicable law. The indemnity provisions
contained herein shall be in addition to any cause of action or
similar rights Indemnitor may have, and any liabilities the
Indemnitor or the Indemnitees may be subject to.

 

 

 

20

 

 

SECTION XI

GOVERNING LAW; DISPUTES SUBMITTED TO ARBITRATION.

 

11.1 LAW
GOVERNING THIS AGREEMENT. This
Agreement shall be governed by and construed in accordance with the
laws of the State of Nevada without regard to principles of
conflicts of laws. Any action brought by either party against the
other concerning the transactions contemplated by this Agreement
shall be brought only in the state or federal courts located in New
York City, New York State. The parties to this Agreement hereby
irrevocably waive any objection to jurisdiction and venue of any
action instituted hereunder and shall not assert any defense based
on lack of jurisdiction or venue or based upon forum non
conveniens. The parties executing this
Agreement and other agreements referred to herein or delivered in
connection herewith on behalf of the Company agree to submit to the
in personam jurisdiction of such courts and hereby irrevocably
waive trial by jury. The
prevailing party shall be entitled to recover from the other party
its reasonable attorney’s fees and costs. In the event that
any provision of this Agreement or any other agreement delivered in
connection herewith is invalid or unenforceable under any
applicable statute or rule of law, then such provision shall be
deemed inoperative to the extent that it may conflict therewith and
shall be deemed modified to conform with such statute or rule of
law. Any such provision which may prove invalid or unenforceable
under any law shall not affect the validity or enforceability of
any other provision of any agreement. Each party hereby irrevocably
waives personal service of process and consents to process being
served in any suit, action or proceeding in connection with this
Agreement or any other Transaction Documents by mailing a copy
thereof via registered or certified mail or overnight delivery
(with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any
way any right to serve process in any other manner permitted by
law.

 

11.2 LEGAL
FEES; AND MISCELLANEOUS FEES.
Except as otherwise set forth in the Registered Offering
Transaction Documents (including but not limited to Section V of
the Registration Rights Agreement), each party shall pay the fees
and expenses of its advisers, counsel, the accountants and other
experts, if any, and all other expenses incurred by such party
incident to the negotiation, preparation, execution, delivery and
performance of this Agreement. Any attorneys’ fees and
expenses incurred by either the Company or the Investor in
connection with the preparation, negotiation, execution and
delivery of any amendments to this Agreement or relating to the
enforcement of the rights of any party, after the occurrence of any
breach of the terms of this Agreement by another party or any
default by another party in respect of the transactions
contemplated hereunder, shall be paid on demand by the party which
breached the Agreement and/or defaulted, as the case may be. The
Company shall pay all stamp and other taxes and duties levied in
connection with the issuance of any Securities.

 

11.3 COUNTERPARTS.
This Agreement may be executed in any number of counterparts and by
the different signatories hereto on separate counterparts, each of
which, when so executed, shall be deemed an original, but all such
counterparts shall constitute but one and the same instrument. This
Agreement may be executed by facsimile transmission, PDF,
electronic signature or other similar electronic means with the
same force and effect as if such signature page were an original
thereof.

 

11.4 HEADINGS;
SINGULAR/PLURAL. The headings
of this Agreement are for convenience of reference and shall not
form part of, or affect the interpretation of, this Agreement.
Whenever required by the context of this Agreement, the singular
shall include the plural and masculine shall include the
feminine.

 

 

 

21

 

 

11.5 SEVERABILITY.
If any provision of this Agreement shall be invalid or
unenforceable in any jurisdiction, such invalidity or
unenforceability shall not affect the validity or enforceability of
the remainder of this Agreement in that jurisdiction or the
validity or enforceability of any provision of this Agreement in
any other jurisdiction.

 

11.6 ENTIRE
AGREEMENT; AMENDMENTS. This
Agreement is the FINAL AGREEMENT between the Company and the
Investor with respect to the terms and conditions set forth herein,
and, the terms of this Agreement may not be contradicted by
evidence of prior, contemporaneous, or subsequent oral agreements
of the Parties. No provision of this Agreement may be amended other
than by an instrument in writing signed by the Company and the
Investor, and no provision hereof may be waived other than by an
instrument in writing signed by the party against whom enforcement
is sought. The execution and delivery of the Registered Offering
Transaction Documents shall not alter the force and effect of any
other agreements between the Parties, and the obligations under
those agreements.

 

11.7 NOTICES.
Any notices or other communications required or permitted to be
given under the terms of this Agreement must be in writing and will
be deemed to have been delivered (I) upon receipt, when delivered
personally; (II) upon receipt, when sent by facsimile (provided
confirmation of transmission is mechanically or electronically
generated and kept on file by the sending party); or (III) one (1)
day after deposit with a nationally recognized overnight delivery
service, in each case properly addressed to the party to receive
the same. The addresses and facsimile numbers for such
communications shall be:

 

	

If to
the Company:

	
 

	

Sunshine
Biopharma, Inc.

6500 Trans-Canada Highway,4th Floor

Pointe-Claire, Quebec, Canada H9R 0A5

	
 

	
 

	
 

	

If to
the Investor:

 

 

 

	
 

	

GHS
Investments, LLC

420
Jericho Turnpike, Suite 207Jericho, NY 11753

 

Each
party shall provide five (5) days prior written notice to the other
party of any change in address or facsimile number.

 

11.8 NO
ASSIGNMENT. This Agreement may
not be assigned.

 

11.9 NO
THIRD PARTY BENEFICIARIES. This
Agreement is intended for the benefit of the parties hereto and is
not for the benefit of, nor may any provision hereof be enforced
by, any other person, except that the Company acknowledges that the
rights of the Investor may be enforced by its general
partner.

 

11.10 SURVIVAL.
The representations and warranties of the Company and the Investor
contained in Sections 3 and 4, the agreements and covenants set
forth in Sections 5 and 6, and the indemnification provisions set
forth in Section
10, shall survive each of the
Closings and the termination of this Agreement.

 

 

 

22

 

 

11.11 PUBLICITY.
The Investor acknowledges that this Agreement and all or part of
the Registered Offering Transaction Documents may be deemed to be
“material contracts” as that term is defined by Item
601(b)(10) of Regulation S-K, and that the Company may therefore be
required to file such documents as exhibits to reports or
registration statements filed under the 1933 Act or the 1934 Act.
The Investor further agrees that the status of such documents and
materials as material contracts shall be determined solely by the
Company, in consultation with its counsel.

 

11.12 FURTHER
ASSURANCES. Each party shall do
and perform, or cause to be done and performed, all such further
acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as the other
party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of
the transactions contemplated hereby.

 

11.13 PLACEMENT
AGENT. If so required, the
Company agrees to pay a registered broker dealer, to act as
placement agent, a percentage of the Put Amount on each Put toward
the fee as outlined in that certain placement agent agreement
entered into between the Company and the placement agent. The
Investor shall have no obligation with respect to any fees or with
respect to any claims made by or on behalf of other persons or
entities for fees of a type contemplated in this Section that may
be due in connection with the transactions contemplated by the
Registered Offering Transaction Documents. The Company shall
indemnify and hold harmless the Investor, their employees,
officers, directors, agents, and partners, and their respective
affiliates, from and against all claims, losses, damages, costs
(including the costs of preparation and attorney’s fees) and
expenses incurred in respect of any such claimed or existing fees,
as such fees and expenses are incurred.

 

11.14 NO
STRICT CONSTRUCTION. The
language used in this Agreement will be deemed to be the language
chosen by the parties to express their mutual intent, and no rules
of strict construction will be applied against any party, as the
parties mutually agree that each has had a full and fair
opportunity to review this Agreement and seek the advice of counsel
on it.

 

11.15 REMEDIES.
The Investor shall have all rights and remedies set forth in this
Agreement and the Registration Rights Agreement and all rights and
remedies which such holders have been granted at any time under any
other agreement or contract and all of the rights which the
Investor has by law. Any person having any rights under any
provision of this Agreement shall be entitled to enforce such
rights specifically (without posting a bond or other security), to
recover damages by reason of any default or breach of any provision
of this Agreement, including the recovery of reasonable attorneys
fees and costs, and to exercise all other rights granted by
law.

 

11.16 PAYMENT
SET ASIDE. To the extent that
the Company makes a payment or payments to the Investor hereunder
or under the Registration Rights Agreement or the Investor enforces
or exercises its rights hereunder or thereunder, and such payment
or payments or the proceeds of such enforcement or exercise or any
part thereof are subsequently invalidated, declared to be
fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the
Company, a trustee, receiver or any other person under any law
(including, without limitation, any bankruptcy law, state or
federal law, common law or equitable cause of action), then to the
extent of any such restoration the obligation or part thereof
originally intended to be satisfied shall be revived and continued
in full force and effect as if such payment had not been made or
such enforcement or setoff had not occurred.

 

11.17 PRICING
OF COMMON STOCK. For purposes
of this Agreement, the price of the Common Stock shall be as
reported by Quotestream Media.

 

 

23

 

 

SECTION XII

NON-DISCLOSURE OF NON-PUBLIC INFORMATION

 

The
Company shall not disclose non-public information to the Investor,
its advisors, or its representatives.

 

Nothing
herein shall require the Company to disclose non-public information
to the Investor or its advisors or representatives, and the Company
represents that it does not disseminate non-public information to
any investors who purchase stock in the Company in a public
offering, to money managers or to securities analysts, provided,
however, that notwithstanding anything herein to the contrary, the
Company will, as hereinabove provided, immediately notify the
advisors and representatives of the Investor and, if any,
underwriters, of any event or the existence of any circumstance
(without any obligation to disclose the specific event or
circumstance) of which it becomes aware, constituting non-public
information (whether or not requested of the Company specifically
or generally during the course of due diligence by such persons or
entities), which, if not disclosed in the prospectus included in
the Registration Statement would cause such prospectus to include a
material misstatement or to omit a material fact required to be
stated therein in order to make the statements, therein, in light
of the circumstances in which they were made, not misleading.
Nothing contained in this Section 12 shall be construed
to mean that such persons or entities other than the Investor
(without the written consent of the Investor prior to disclosure of
such information) may not obtain non-public information in the
course of conducting due diligence in accordance with the terms of
this Agreement and nothing herein shall prevent any such persons or
entities from notifying the Company of their opinion that based on
such due diligence by such persons or entities, that the
Registration Statement contains an untrue statement of material
fact or omits a material fact required to be stated in the
Registration Statement or necessary to make the statements
contained therein, in light of the circumstances in which they were
made, not misleading.

 

SECTION XIII

ACKNOWLEDGEMENTS OF THE PARTIES

 

Notwithstanding
anything in this Agreement to the contrary, the parties hereto
hereby acknowledge and agree to the following: (i) the Investor
makes no representations or covenants that it will not engage in
trading in the securities of the Company, other than the Investor
will not short the Company’s common stock at any time during
the term of this Agreement; (ii) the Company shall, by 8:30 a.m.
EST on the second Trading Day following the date hereof, file a
current report on Form 8-K disclosing the material terms of the
transactions contemplated hereby and in the other Registered
Offering Transaction Documents; (iii) the Company has not and shall
not provide material non-public information to the Investor unless
prior thereto the Investor shall have executed a written agreement
regarding the confidentiality and use of such information; and (iv)
the Company understands and confirms that the Investor will be
relying on the acknowledgements set forth in clauses (i) through
(iii) above if the Investor effects any transactions in the
securities of the Company.

 

 

Your
signature on this Signature Page evidences your agreement to be
bound by the terms and conditions of the Investment Agreement as of
the date first written above. The undersigned signatory hereby
certifies that he has read and understands the Investment
Agreement, and the representations made by the undersigned in this
Investment Agreement are true and accurate, and agrees to be bound
by its terms.

 

 

 

24

 

 

GHS
INVESTMENTS, LLC

 

 

By:
/s/ Sarfraz
Hajee                                                                           

       Sarfraz
Hajee, Member

 

 

SUNSHINE
BIOPHARMA, INC.

 

 

By:
/s/ Camille
Sebaaly 

       Camille
Sebaaly, Chief Financial Officer

 

 

 

 

 

[SIGNATURE PAGE OF EQUITY FINANCING AGREEMENT]

 

 

 

 

 

 

 

25

 

 

LIST OF EXHIBITS

 

 

 

EXHIBIT
A   

Registration
Rights Agreement

 

EXHIBIT B

 Notice of
Effectiveness

 

EXHIBIT C

Put
Notice

 

EXHIBIT
D     

Put
Settlement Sheet

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

26

 

 

EXHIBIT A

 

REGISTRATION RIGHTS AGREEMENT

 

See attached.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

27

 

 

EXHIBIT B

 

FORM OF NOTICE OF
EFFECTIVENESS

 

OF REGISTRATION STATEMENT

 

Date:
__________

 

[TRANSFER AGENT]

 

            

Re: Sunshine Biopharma Inc.

 

Ladies and Gentlemen:

 

            

We are counsel to Sunshine Biopharma Inc.,
a Colorado corporation (the
“Company”), and have represented the Company in
connection with that certain Equity Financing Agreement (the
“Investment Agreement”) entered into by and among the
Company and GHS Investments, LLC(the “Investor”)
pursuant to which the Company has agreed to issue to the Investor
shares of the Company’s common stock, $0.01 par value per
share (the “Common Stock”) on the terms and conditions
set forth in the Investment Agreement. Pursuant to the Investment
Agreement, the Company also has entered into a Registration Rights
Agreement with the Investor (the “Registration Rights
Agreement”) pursuant to which the Company agreed, among other
things, to register the Registrable Securities (as defined in the
Registration Rights Agreement), including the shares of Common
Stock issued or issuable under the Investment Agreement under the
Securities Act of 1933, as amended (the “1933 Act”). In
connection with the Company’s obligations under the
Registration Rights Agreement, on ____________ ___, 20__, the
Company filed a Registration Statement on Form S- ___ (File No.
__-________) (the “Registration Statement”) with the
Securities and Exchange Commission (the “SEC”) relating
to the Registrable Securities which names the Investor as a selling
shareholder thereunder.

 

            

In
connection with the foregoing, we advise you that a member of the
SEC's staff has advised us by telephone that the SEC has entered an
order declaring the Registration Statement effective under the 1933
Act at ______ on __________, 20__ and we have no knowledge, after
telephonic inquiry of a member of the SEC's staff, that any stop
order suspending its effectiveness has been issued or that any
proceedings for that purpose are pending before, or threatened by,
the SEC and the Registrable Securities are available for sale under
the 1933 Act pursuant to the Registration Statement

 

 

Very
truly yours,

 

 

[Company
Counsel]

 

 

 

28

 

 

EXHIBIT C

 

FORM OF PUT NOTICE

 

 

 

 

Date:

 

RE: Put Notice Number __

 

Dear Mr./Ms.__________,

 

This is to inform you that as of today, Sunshine Biopharma,
Inc., a Colorado corporation (the
“Company”), hereby elects to exercise its right
pursuant to the Equity Financing Agreement to require GHS
Investments LLC to purchase shares of its common stock. The Company
hereby certifies that:

 

The amount of this put is $__________.

 

The Pricing Period runs from _______________ until
_______________.

 

The Purchase Price is: $_______________

 

The number of Put Shares Due: ___________________.

 

The current number of shares of common stock issued and outstanding
is: _________________.

 

The number of shares currently available for issuance on the S-1
is: ________________________.

 

 

 

Regards,

 

Sunshine
Biopharma, Inc.

 

 

By:
__________________________________

Name:
Camille Sebaaly

Title:
Chief Financial Officer

 

 

29

 

 

EXHIBIT D

 

PUT SETTLEMENT SHEET

 

Date: ________________

 

Dear Mr. ________,

 

Pursuant to the Put given by Sunshine Biopharma, Inc.,
to GHS Investments LLC
(“GHS”) on _________________ 201_, we are now
submitting the amount of common shares for you to issue to
GHS.

 

Please have a certificate bearing no restrictive legend totaling
__________ shares issued to GHS immediately and send via DWAC to
the following account:

 

[INSERT]

 

If not DWAC eligible, please send FedEx Priority Overnight
to:

 

[INSERT ADDRESS]

 

Once these shares are received by us, we will have the funds wired
to the Company.

 

Regards,

 

GHS INVESTMENTS LLC

 

 

By:
__________________________________

Name:

Title:

 

 

 

30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]